33.49
Beam Therapeutics Inc stock is traded at $33.49, with a volume of 2.01M.
It is up +3.36% in the last 24 hours and up +42.88% over the past month.
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.
See More
Previous Close:
$32.40
Open:
$33.76
24h Volume:
2.01M
Relative Volume:
1.74
Market Cap:
$2.77B
Revenue:
$352.57M
Net Income/Loss:
$-143.01M
P/E Ratio:
-18.50
EPS:
-1.81
Net Cash Flow:
$-153.40M
1W Performance:
+24.73%
1M Performance:
+42.88%
6M Performance:
+37.09%
1Y Performance:
+1.79%
Beam Therapeutics Inc Stock (BEAM) Company Profile
Name
Beam Therapeutics Inc
Sector
Industry
Phone
857-327-8775
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
BEAM
Beam Therapeutics Inc
|
33.49 | 2.77B | 352.57M | -143.01M | -153.40M | -1.81 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
462.11 | 118.67B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
680.00 | 74.34B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
639.00 | 38.83B | 1.86B | -40.29M | -1.28B | -0.85 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
250.00 | 32.36B | 2.09B | -332.26M | 16.06M | -2.62 |
![]()
BNTX
Biontech Se Adr
|
122.75 | 29.43B | 3.30B | -501.07M | 1.03B | -2.1146 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-29-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
Nov-06-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
Jul-23-24 | Initiated | H.C. Wainwright | Buy |
Jan-29-24 | Upgrade | JP Morgan | Neutral → Overweight |
Dec-15-23 | Downgrade | BofA Securities | Buy → Neutral |
Dec-08-23 | Downgrade | Jefferies | Buy → Hold |
Oct-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Oct-20-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
Mar-21-23 | Initiated | Bernstein | Mkt Perform |
Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
Dec-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
Dec-13-22 | Initiated | Citigroup | Buy |
Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
Apr-28-22 | Initiated | Credit Suisse | Neutral |
Jan-05-22 | Initiated | Guggenheim | Buy |
Oct-19-21 | Initiated | SVB Leerink | Outperform |
Sep-24-21 | Resumed | Stifel | Buy |
Sep-10-21 | Initiated | BofA Securities | Buy |
May-11-21 | Initiated | Redburn | Buy |
May-04-21 | Initiated | RBC Capital Mkts | Sector Perform |
Mar-01-21 | Downgrade | Barclays | Overweight → Equal Weight |
Feb-16-21 | Initiated | Wells Fargo | Overweight |
Jan-29-21 | Downgrade | JP Morgan | Overweight → Neutral |
Jan-06-21 | Initiated | Stifel | Hold |
Aug-05-20 | Initiated | William Blair | Outperform |
Mar-02-20 | Initiated | Barclays | Overweight |
Mar-02-20 | Initiated | JP Morgan | Overweight |
Mar-02-20 | Initiated | Jefferies | Buy |
Mar-02-20 | Initiated | Wedbush | Outperform |
View All
Beam Therapeutics Inc Stock (BEAM) Latest News
Cathie Wood's ARK ETF adds Twist Bioscience, Beam Therapeutics stock - Investing.com
Beam Therapeutics (NASDAQ:BEAM) Stock Price Up 17.9%Here's What Happened - MarketBeat
Beam Therapeutics (BEAM) to Release Earnings on Tuesday - MarketBeat
Baillie Gifford & Co. Decreases Stock Position in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Next Generation Genome Editing Market Top Companies Study - openPR
C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Buys Shares of 13,287 Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Short Interest in Beam Therapeutics Inc. (NASDAQ:BEAM) Drops By 7.1% - MarketBeat
Beam Therapeutics to present updated BEAM-101 trial data - MSN
Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Peregrine Investment Management Inc. Takes $3.93 Million Position in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
(BEAM) Technical Data - Stock Traders Daily
Cathie Wood's Ark Invest Loads Up On Iridium, Twist Bioscience, Offloads Roku: Here Are Key Ark Trades This Friday - Benzinga
Goodyear Tire & Rubber Posts Upbeat Results, Joins Nu Skin, Pacific Biosciences of California, Airbnb, Roku And Other Big Stocks Moving Higher On Friday - Benzinga India
Wall Street Analysts See a 67.27% Upside in Beam Therapeutics (BEAM): Can the Stock Really Move This High? - Yahoo Finance
Is Beam Therapeutics (BEAM) Outperforming Other Medical Stocks This Year? - MSN
Sumitomo Mitsui Trust Group Inc. Acquires 404,782 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics (BEAM) Stock Price, News & Analysis - MarketBeat
BMO Capital maintains Outperform on Beam Therapeutics stock By Investing.com - Investing.com Nigeria
BMO Capital maintains Outperform on Beam Therapeutics stock - MSN
Beam Therapeutics (NASDAQ:BEAM) Trading 8% HigherShould You Buy? - MarketBeat
FY2026 Earnings Estimate for BEAM Issued By HC Wainwright - MarketBeat
Brokers Issue Forecasts for BEAM Q1 Earnings - MarketBeat
HC Wainwright Reiterates "Buy" Rating for Beam Therapeutics (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics Inc. (NASDAQ:BEAM) CEO Sells $802,500.00 in Stock - MarketBeat
H.C. Wainwright maintains $80 target on Beam Therapeutics stock - MSN
(BEAM) Long Term Investment Analysis - Stock Traders Daily
FY2024 EPS Forecast for Beam Therapeutics Boosted by Analyst - MarketBeat
H.C. Wainwright maintains $80 target on Beam Therapeutics stock By Investing.com - Investing.com Canada
Beam Therapeutics (NASDAQ:BEAM) Shares Gap UpWhat's Next? - MarketBeat
Gene Editing: CRISPR Therapeutics vs. Beam Therapeutics - Securities.io
(BEAM)Analyzing Beam Therapeutics's Short Interest - Benzinga
Beam Therapeutics Inc.'s (NASDAQ:BEAM) Prospects Need A Boost To Lift Shares - Simply Wall St
Investors in Beam Therapeutics (NASDAQ:BEAM) from three years ago are still down 55%, even after 3.8% gain this past week - Yahoo Finance
Beam Therapeutics Inc Stock (BEAM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):